drugset / Trial / NCT00301847

Sorafenib in Treating Patients With Kidney Cancer That Has Spread to the Brain

NCT00301847 ↗

Phase 2 Completed 44 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase II trial is studying how well sorafenib works in treating patients with kidney cancer that has spread to the brain. Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Timeline

Start
2005-11
Primary completion
2007-06
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Sorafenib Small molecule — Oral